HOME
ABOUT US
OUR COMPANY
OUR TEAM
BOARD OF DIRECTORS
INVESTORS
CAREERS
T-GUARD®
CHARACTERISTICS
DEVELOPMENT PLAN
GRAFT-VERSUS-HOST
ADDITIONAL INDICATIONS
EXPANDED ACCESS
A PATIENT’S STORY
NEWS & EVENTS
NEWS
EVENTS
IN THE MEDIA
PUBLICATIONS
PARTNERING
PARTNERING FOR PROGRESS
CONTACT
✕
NEWS
Filter by
Languages
Skill level
Authors
Show all
All
Press-releases
All
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
All
MauriceHampsink
18 december 2019
18 december 2019
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial
3 december 2019
3 december 2019
Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting
2 december 2019
2 december 2019
Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer
Load more